Revised forecast
Fiscal year ending December 2026 · Full yearPrevious forecast published 13 February 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document.
The company is examining the impact on earnings because unit sales prices have not increased sufficiently during the process of responding to the new system following the June 2026 revision of medical fees, and utilization has declined following a review of residential rents and other costs. As the new reimbursement system has only recently been introduced, calculating a reasonable earnings forecast at this time is difficult, so the forecast is being withdrawn for the time being.
| Item | Details |
|---|---|
| Net Sales | ¥16,500 million → To be determined |
| Operating profit | ¥1,500 million → To be determined |
| Ordinary income | ¥1,000 million → To be determined |
| Profit attributable to owners of the parent | ¥600 million → To be determined |
| Net income per share | 71.2 yen → To be determined |
| Fiscal Period Covered | Fiscal year ending December 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 13 February 2026 |
| Previous-period results | Revenue: ¥14,168 million; operating profit: ¥849 million; ordinary profit: ¥550 million; net profit attributable to owners of the parent: ¥278 million; net profit per share: ¥33.07 (fiscal year ended December 2025) |
| Reason for the revision | The company is examining the impact on earnings because unit sales prices have not increased sufficiently during the process of responding to the new system following the June 2026 revision of medical fees, and utilization has declined following a review of residential rents and other costs. As the new reimbursement system has only recently been introduced, calculating a reasonable earnings forecast at this time is difficult, so the forecast is being withdrawn for the time being. |
| Dividend forecast revision | The year-end dividend forecast has been changed from ¥25.00 to undetermined, and the total annual dividend has likewise been changed from ¥25.00 to undetermined. The second-quarter-end dividend is ¥0.00. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (1)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company is examining the impact on earnings because unit sales prices have not increased sufficiently during the process of responding to the new system following the June 2026 revision of medical fees, and utilization has declined following a review of residential rents and other costs. It determined that calculating a reasonable earnings forecast would be difficult immediately after the new system was introduced.